Hepatocellular Carcinoma
Conditions
Brief summary
Clinical research of Yang Yin Fu Zheng therapy in HBV associated hepatocellular carcinoma basing on immune microenviroment.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng therapy for patients belong to HBV-HCC.
Interventions
DRUGYang Yin Fu Zheng therapy
Yang Yin Fu Zheng is a Chinese herbal compound.
Routine medical care
Sponsors
Beijing Ditan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed of stage HBV-HCCⅡb、Ⅲa、Ⅲb; 2. Ages Eligible for Study: ≤75 years old; 3. TCM syndrome is deficiency of both Qi and Yin; 4. Confirmed of CHB; 5. Surgery cannot be allowed; 6. Informed consent from the patient.
Exclusion criteria
1. Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD; 2. Serious problem of heart, lung, or kidney with severe dysfunction; 3. Pregnant or child breast feeding women; 4. Mental or cognitive disorders; 5. Participating in other drug trials; 6. Who are allergic to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate | 2 years |
| quality of life(QOL) | 2 years |
Countries
China
Outcome results
None listed